Market Place
Sourcing Support
DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions
The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions t
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though
FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024
The year 2024 was marked by some landmark drug approvals in the areas of schizophrenia, metabolic dy
Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments
This year has seen pivotal advancements in medical innovation. The US Food and Drug Administration (
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
